Improving patient safety through medicine risk communication: a theory-informed evaluation approach

AI and machine learning for predicting in vitro/preclinical drug toxicities and adverse events in clinical patients

Pharmacovigilance Signals and Determinants of Adverse Events Linked to Inhaled Asthma Medications: A Retrospective Analysis Using the FAERS Database

Pharmacovigilance in Antituberculosis Treatment: Ensuring Safety in Tuberculosis Management

How Machine Learning Can Help Close Evidence Gaps for Drug Safety in Pregnant Women

Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study

Interpol alerta del auge de antiparasitarios veterinarios promovidos como tratamientos contra el cáncer en humanos

Deviations from recommended use of liposomal bupivacaine: a real-world pharmacovigilance study using the FAERS database

Knowledge Graph for Cardiovascular Drug Safety and Pharmacovigilance: A Scoping Review

79th World Health Assembly adopts resolution to strengthen pharmacovigilance

Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65 years: Based on the FDA adverse event reporting system (FAERS)

Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies

Sex-specific risk profiles of drug-associated joint stiffness and deformity: a FAERS-based pharmacovigilance study with Canadian Vigilance Adverse Reaction Database validation

Quality of adverse drug reaction reports submitted to the national pharmacovigilance center of Nepal: a pre-and post-training evaluation

WHO and African Medicines Agency launch landmark framework to strengthen access to quality-assured health products in Africa

Adverse Effects and Treatment Discontinuation of Blood Pressure–Lowering Drugs and Combinations. A Network Meta-Analysis

Minimizing Adverse Effects in Hypertension Treatment

The High Stakes of Pharmacovigilance: Why Specialized Partnership Outperforms the Large CRO Model

Immunomodulatory therapies and emerging drug associations with microscopic colitis: A global pharmacovigilance analysis

Counterfeit anti-rabies vaccine as a neglected issue: a manufacturers’ perspective

Association between ranitidine use and thyroid cancer based on FAERS and VigiAccess databases

Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System

Knowledge, attitude, and practice of undergraduate medical students toward pharmacovigilance and adverse drug reaction reporting: A questionnaire-based study

Post-marketing safety concerns with foscarbidopa/foslevodopa: A pharmacovigilance study with disproportionality analysis based on FAERS

Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports

Turning the tide on substandard and falsified medicines – the Medicine Quality, Innovation & Policy Conference, April 2026

How the VMD monitors the safety of animal medicines

Antibiotic Stewardship: Five Tips to Reduce Resistance

When Medicines Harm: A Systems Analysis of the 2022 Paediatric Acute Kidney Injury Epidemic in The Gambia

Disproportionality and Case-Based Evidence for a Possible Association Between Fluoroquinolones and Kounis Syndrome

Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database

Paroxysmal Nocturnal Hemoglobinuria and Vaccination: A Systematic Pharmacovigilance Analysis of 147 Cases

A real-world pharmacovigilance analysis of cardiac, endocrine, and neurological adverse events associated with cabergoline: a disproportionality study

Integrating pharmacovigilance into quality and regulatory decision making: A systematic review

INTELIGENCIA ARTIFICIAL Y MEDICINA: DIEZ LECCIONES APRENDIDAS (Y OLVIDADAS): 1970-2026

Pharmacovigilance in Ayurveda: Ensuring Safe Use of Traditional Medicines

Prescription safety in elderly cardiology patients: a cross-sectional study

Optimizing cardiac patients safety: Assessing QT interval-prolonging drug alert in electronic prescription in hospitalized patients

Alerta de circulación irregular de fármacos para uso animal

Strengthening Global Drug and Vaccine Safety Through AI-Driven Pharmacovigilance: Myocarditis Signals, mRNA Vaccine AEFIs, and PV Infrastructure Assessment

Aligned MHRA-NICE approval pathway benefits industry over patients

How Advanced Technology Is Reshaping Medication Safety and Pharmacy Practice

Integrating Vadadustat into Pharmaceutical Care for CKD-Related Anemia: Evidence-Based and Pharmacovigilance Perspectives

Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis

Drug Recall Systems in Pharmaceutical Regulation: Regulatory Frameworks, Procedures, and Global Perspectives

Connecticut AG’s crackdown leads to major platform halting sales of “research grade” weight loss chemicals to U.S.

Boletín sobre Seguridad de Medicamentos de Uso Humano. Marzo de 2026

ANMAT cancela la autorización de medicamentos con hidroxietil almidón (HEA) y poli(O-2-hydroxietil)-almidón (HEA) para infusión

Proactive drug safety surveillance should be at the heart of the new Health Data Research Service

Prenatal Azithromycin Exposure and Risk of Neurodevelopmental Disorders in Children

Race, Ethnicity, and Language Disparities in Alcohol and Drug Screening and Medication Treatment

Commission welcomes political agreement on Critical Medicines Act

AI-Based Automation for Medication Reconciliation: Scoping Review

The First AI Drug Prescriber

The Burden of Inappropriate Polypharmacy: Approaches to Improve Medication Safety

Factors influencing identification capability of adverse drug reactions in children aged 8–18 years based on social cognitive theory

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

Details of oral anticancer drug prescription audits by community pharmacists: a retrospective analysis of prescription inquiries

Branding en “contextos sensibles”: la seguridad en el packaging farmacéutico en personas mayores a través del análisis de la isoapariencia visual y verbal

Counterfeit Chronicles: Describing and Explicating Online Advertising for Counterfeit Products

BERT-Based Models for Normalization of Adverse Drug Event Expressions in Social Media to Standard Medical Terminology for Drug Safety Analysis

Personalized Dosage System as a Tool for Detecting Adverse Drug Reactions: Pharmaceutical Intervention in a Polymedicated Patient

The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy

Disproportionality Analysis and Timing of Drug-Associated Guillain–Barré Syndrome Onset Based on the Japanese Adverse Drug Event Report Database

The Role of Electronic Medical Record Systems and Pharmacovigilance Databases in the Surveillance of Antimicrobial Use and Resistance in Low- and Middle-Income Countries: Protocol for a Multistudy Project

Pharmacovigilance analysis and real-world adverse event profile (safety signals and product-related issues) of potassium citrate: a US FDA adverse event reporting system (FAERS) based analysis

Interstitial lung disease associated with novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database

Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review

Antibiotic-associated encephalopathy: A retrospective pharmacovigilance study based on 21 years of data from the US FDA Adverse Event Reporting System

Prescribing trends and spontaneous reporting patterns of adverse drug reactions of ADHD medications in children and adolescents in germany: A retrospective analysis (2013–2022)

Continued Use of Medications Withdrawn Internationally for Safety Concerns: Insights from an Urban Employed Population in China

Trends in adverse drug reaction reporting by dentists: a 15-year analysis of German pharmacovigilance data

FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics

MHRA strengthens safety warnings for finasteride and dutasteride

Inoculation: A Vaccine Against Anti-vaccine Arguments

Combination therapy and its resistance in the development of antimalarial drugs

Cardiac Safety of Intranasal Chlorpheniramine: An Exposure-Based Risk Assessment

Drug Safety for Lactating Women: Still a Forgotten Frontier?

Counterfeit anti-rabies vaccine as a neglected issue: a manufacturers’ perspective

ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database

Pharmacovigilance and toxicological studies on safety signals associated with the combined use of propofol and midazolam

Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs)

Assessing safety in the RTS,S/AS01 malaria vaccine implementation programme: an overview and comparison of methods

Efficacy and Safety of Digitalis Glycosides in Heart Failure. A Meta-Analysis

Precautionary recall of antidepressant medication due to manufacturing error

La OMS rechaza nuevamente la inclusión del metilfenidato para el TDAH en su lista de medicamentos esenciales

Fake Malaria Drugs Undermine Africa’s Fight

Global crackdown on illicit pharmaceuticals sees USD 15.5 million in seizures

Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics

La AEMPS adecúa los formatos de antibióticos para alinearlos con las pautas clínicas habituales y evitar su uso inapropiado

New Drugs Are Primary Care Game Changers, but Pricey

Comparative Cardiovascular Safety of Prescription Amphetamine and Methylphenidate Initiation Among Older Adult Medicare Beneficiaries

AI Drug Safety in Pregnancy

Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system

Drug-induced neutropenia: A comprehensive pharmacovigilance study of the FAERS database

Identifying High‐Risk Medications for Drug‐Induced Dystonia: A 20‐Year Retrospective Real‐World Pharmacovigilance Study Based on FAERS

Exploring Risk Drugs and Mechanisms in Dystonia: Insights from Pharmacovigilance and Proteogenomics

Boletín sobre Seguridad de Medicamentos de Uso Humano. Febrero de 2026